Evommune vs HCW Biologics
EVMN and HCWB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVMN and HCWB compare
Evommune is the larger company, worth 195 times as much as HCW Biologics ($277M against $1.4M).
HCW Biologics grew revenue faster over the last twelve months (700% versus −100% for Evommune).
Evommune scores higher on the StockData Score (7 against 6 for HCW Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVMN | HCWB |
|---|---|---|
| Size and price | ||
| Market cap | $277M | $1.4M |
| Share price | $7.63 | $0.773 |
| Change, 1 year | −60.9% | −95.0% |
| Change, 5 years | – | −99.9% |
| Beta (5Y) | 0.79 | 0.74 |
| Employees | 48 | – |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.2× |
| P/B | 1.1× | 0.2× (better) |
| FCF yield | −32.9% | – |
| Fair value | – | $14.72 |
| Margin of safety | – | 94.7% |
| Growth | ||
| Revenue growth (TTM) | −100% | 700% (better) |
| Revenue growth, 5Y average | – | −57.9% |
| Profitability | ||
| Gross margin | – | 96.7% |
| Operating margin | – | −115% |
| Net margin | – | −83.8% |
| Return on equity | −331% | −151% (better) |
| Return on invested capital | – | −70.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.88 (better) |
| Interest coverage | – | −14.0× |
| Current ratio | 8.52 (better) | 0.06 |
| Altman Z-score | 3.85 (better) | −7.21 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 95.4% | 5.6% |
| Held by insiders | 51.6% | 34.9% |
| Insider net buying, 12 months | −$2.1M | $532K (better) |
| Short interest, % of float | 19.3% | 4.1% |
Go deeper
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
- HCWB stock overview
- HCWB income statement
- HCWB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.